•

COVID-19 is associated with specific skin manifestations and drug eruption.

  • •

    This case shows COVID-19–related drug eruption and specific clinical features.

  • •
    • …">

    Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? - PubMed (original) (raw)

    Case Reports

    Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?

    Takashi Sakaida et al. J Dermatol Sci. 2020 Jul.

    Abstract

    1. •
      COVID-19 is associated with specific skin manifestations and drug eruption.
    2. •
      This case shows COVID-19–related drug eruption and specific clinical features.
    3. •
      Drug eruption preceding COVID-19 symptoms may facilitate early diagnosis.

    PubMed Disclaimer

    Conflict of interest statement

    Declaration of Competing Interest No conflict of interest.

    Figures

    Fig. 1

    Fig. 1

    Clinical features of her trunk and leg Day 0, indurated erythema on her leg, and red papules and erythema on her trunk Day 8, dark red colored papules and indurated erythema were largely observed on her leg and trunk.

    Fig. 2

    Fig. 2

    Pathologic findings (Day 0 and Day 8). (A, B): Pathologic analysis of a skin biopsy sample obtained from an indurated erythematous lesion (Day 0). The size of bar is indicated in the figure. (C, D): Pathologic analysis of a skin biopsy sample from an abdominal lesion. Interface changes with liquefaction and perivascular mixed cell infiltrations in the papillary dermis are observed. There are histiocytic infiltrations around the capillary vessels and neutrophils are scattered in the upper dermis (C–D). The size of bar is indicated in the figure.

    Similar articles

    Cited by

    References

      1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. - PMC - PubMed
      1. Zheng Y., Lai W. Dermatology staff participate in fight against Covid-19 in China. J. Eur. Acad. Dermatol. Venereol. 2020 doi: 10.1111/jdv.16390. [Epub ahead of print: Mar 23, 2020] - DOI - PubMed
      1. Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q., Akdis C.A., Gao Y.D. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 doi: 10.1111/all.14238. [Epub ahead of print: Feb 19, 2020] - DOI - PubMed
      1. Wu D., Yang X.O. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J. Microbiol. Immunol. Infect. 2020 doi: 10.1016/j.jmii.2020.03.005. [Epub ahead of print: Mar 11, 2020] - DOI - PMC - PubMed
      1. Russell B., Moss C., Rigg A., Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023. - PMC - PubMed

    Publication types

    MeSH terms

    Substances

    LinkOut - more resources